Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598677 | 0.78 | MKNK1 (0.42) | KMT2AKDM4E | |
| SCHEMBL5851859 | 0.71 | PDE1A (0.37) | ALDH1A1KMT2AMEN1AKR1C3NR4A1 | |
| SCHEMBL11172108 | 0.70 | CDK2 (0.53) | — | |
| SCHEMBL22490646 | 0.68 | CCNE1 (0.38) | — | |
| SCHEMBL5073237 | 0.67 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1AKR1C3NR4A1 | |
| SCHEMBL3709112 | 0.66 | SMN1; SMN2 (0.67) | ALDH1A1KMT2AMEN1AKR1C3NR4A1 | |
| SCHEMBL10554596 | 0.66 | IRAK4 (0.57) | KDM4E | |
| SCHEMBL5076643 | 0.65 | ALDH1A1 (0.62) | ALDH1A1KMT2AMEN1AKR1C3KDM4E | |
| SCHEMBL5001988 | 0.64 | AKR1C3 (0.44) | ALDH1A1KMT2AMEN1AKR1C3NR4A1 | |
| SCHEMBL19554105 | 0.64 | MYC (0.45) | ALDH1A1KMT2AMEN1NR4A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984646-B2 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALHCARE AG (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1412353-B1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1412353-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008413-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | MAPK1, MAPK3, MAP3K1 | ALDH1A1 1216/4885TNK2 85/4885KMT2A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.